Abstract
It has recently been proven that D-penicillamine (D-Pc) is an effective agent in the management of patients with rheumatoid arthritis.
D-Pc was shown to have an inhibitory effect on the formation of antibodies against sheep red blood cells (SRBC) and, more specifically, against antibody-producing cells after long-term treatment of rats before inoculation with SRBC. D-Pc was also shown to act inhibitorily on adjuvant arthritis in rats and DNCB contact dermatitis in guineapigs. It was suggested that the mechanism of action of D-Pc on rheumatoid arthritis was the inhibitory effects of D-Pc on both humoral and cellular immunity.
